Arecor Therapeutics (LON:AREC) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?

Arecor Therapeutics plc (LON:AREC) shares crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of GBX 80.58 and traded as high as GBX 81.50. Arecor Therapeutics shares last traded at GBX 81.50, with a volume of 2,750 shares traded.

Arecor Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.55, a current ratio of 4.29 and a quick ratio of 6.24. The firm has a market capitalization of £33.98 million, a price-to-earnings ratio of 75.00 and a beta of -0.18. The stock has a 50 day moving average price of GBX 80.58 and a two-hundred day moving average price of GBX 70.98.

Arecor Therapeutics (LON:AREC) last posted its earnings results on Thursday, October 1st. The company reported GBX (8) earnings per share (EPS) for the quarter. Arecor Therapeutics had a positive return on equity of 3.75% and a negative net margin of 200.00%. As a group, analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.